Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension of Monepantel in Motor Neurone Disease
NCT06177431Phase 1Completed
- Sponsor
- Neurizon Therapeutics
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of monepantel in motor neuron disease (MND), sponsored by Neurizon Therapeutics. Primary endpoint: Long-term safety and tolerability at 12 months. Started Feb 2024; status: completed.
02
Drugs
monepantel
03
Conditions
motor neuron disease (MND)
Beyond the preview
Go deeper on NCT06177431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177431.